Kiniksa Pharmaceuticals
KNSA
56 hedge funds and large institutions have $295M invested in Kiniksa Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 6 reducing their positions, and 5 closing their positions.
513% more capital inflows, than outflows
Capital inflows: $87.8M | Capital outflows: $14.3M
400% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 6
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
10% more funds holding
Funds holding: 51 → 56 (+5)
8.45% more ownership
Funds ownership: 79.1% → 87.56% (+8.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$31.1M |
| 2 |
Vivo Capital
Palo Alto,
California
|
+$11.2M |
| 3 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$8.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.53M |
| 5 |
BlackRock
New York
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.8M |
| 2 |
Millennium Management
New York
|
-$1.46M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.25M |
| 4 |
Algert Global
San Francisco,
California
|
-$300K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$247K |
KNSA Hedge Fund Activity: Q1 2019 in Review
56 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2019, worth a combined $295M — down 23% from $385M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KNSA positions and 5 closed out — a net gain of 4 holders — while 30 added to existing stakes and 6 trimmed.
The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $31.1M. The largest seller was Cormorant Asset Management, cutting an estimated $10.8M.
- 56 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2019, up from 51 in Q4 2018.
- Funds reported $295M of Kiniksa Pharmaceuticals stock for Q1 2019, down 23% quarter-over-quarter.
- 9 funds opened new Kiniksa Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of +4 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2019 was ArrowMark Colorado Holdings, an estimated $31.1M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2019.